Most Recent
Mills Oakley partner ordered to pay $308,000 to former firm
A judge has ordered a Mills Oakley partner to pay his former law firm over $300,000 after finding he had overdrawn his share of the partnership income.
Lawyers for sacked Webjet counsel told off for ‘bombarding’ chambers
A judge has scolded lawyers acting for Webjet's former chief legal officer in an unfair dismissal case against the online travel agency for "bombarding" his chambers with submissions minutes before a hearing.
IAG pitches benefits of RACWA tie-up, offers sweeteners to ACCC
IAG said Wednesday it had offered a range of commitments to sweeten its proposed $1.35 billion merger with vehicle insurer RACWA as it promotes the benefits of the union to the competition regulator.
ASIC urged to scrutinise Firmus’ failed public float
Liberal senator Dave Sharma has called on ASIC to scrutinise AI data centre company Firmus' withdrawn initial public offering, including representations made to investors.
Albanese government defends social media ban in High Court
The government has hit back at a High Court case by two high school students alleging its under-16s social media ban infringes on the implied freedom of political communication, arguing that any restriction is justified. 
Abbey Laboratories proves honest use of ‘Virkill’ trade mark
Animal health giant Abbey Laboratories has fought off a challenge to its bid to register 'Virkill' as a trade mark for its disinfectant products, despite an IP Australia delegate finding the name was deceptively similar to its opponent's 'Virukill' mark.
Hugo Boss shoots down ‘Mafiaboss’ trade marks
Hugo Boss AG has successfully opposed an application to trade mark 'Mafiaboss' for clothing, footwear and leather goods, with a delegate finding the addition of 'mafia' was not enough to distinguish the trade marks.
Oh snap! Snapchat locked in trade mark fight with Aussie printing company
Snapchat is gearing up for a fight with Australian print franchise Snap over its plans to register 'Snapchat Ads' as a trade mark. 
CSL strikes $2.24B deal with Alentis for rare disease drug
Australian biotech CSL has inked an agreement with Swiss company Alentis Therapeutics to develop and commercialise an experimental antibody treatment for rare kidney and liver diseases in a deal worth up to $2.24 billion. 
Ferro-grad C maker Arrotex hits back at Aspen over ‘superiority’ claim
Arrotex has hit back at a lawsuit by the maker of Maltofer iron supplements, filing a cross-claim alleging its rival’s advertising was false because it conveyed its product was superior to Ferro-grad C.